United Laboratories Reports Positive China Phase 2 Results for Obesity Drug

MT Newswires Live09:48

United Laboratories International (HKG:3933) said its Phase 2 clinical trial of UBT251 Injection, a Class 1 innovative drug developed by its wholly owned unit, has been completed in Chinese patients with overweight and obesity, according to a Tuesday Hong Kong bourse filing.

Shares of the company gained over 3% in Wednesday morning trade.

The randomized, double-blind, placebo-controlled study enrolled 205 patients with obesity or overweight accompanied by at least one weight-related comorbidity.

Participants received weekly subcutaneous injections of UBT251 at 2 mg, 4 mg, or 6 mg, or placebo, over 24 weeks.

At week 24, the maximum mean reduction in body weight reached 19.7% or 17.5 kg in the UBT251 groups, compared with 2% or 1.6 kg in the placebo group.

The company said all dose groups demonstrated significant improvements in secondary endpoints, including waist circumference, blood glucose, blood pressure, and blood lipids.

The company plans to initiate a Phase 3 trial in China in due course.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614347778?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 09:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614347778","market":"sh","top_or_hot":-1,"title":"United Laboratories Reports Positive China Phase 2 Results for Obesity Drug","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ULIHF\">United Laboratories</a> International (HKG:3933) said its Phase 2 clinical trial of UBT251 Injection, a Class 1 innovative drug developed by its wholly owned unit, has been completed in Chinese patients with overweight and obesity, according to a Tuesday Hong Kong bourse filing.</p><p>Shares of the company gained over 3% in Wednesday morning trade.</p><p>The randomized, double-blind, placebo-controlled study enrolled 205 patients with obesity or overweight accompanied by at least one weight-related comorbidity.</p><p>Participants received weekly subcutaneous injections of UBT251 at 2 mg, 4 mg, or 6 mg, or placebo, over 24 weeks.</p><p>At week 24, the maximum mean reduction in body weight reached 19.7% or 17.5 kg in the UBT251 groups, compared with 2% or 1.6 kg in the placebo group.</p><p>The company said all dose groups demonstrated significant improvements in secondary endpoints, including waist circumference, blood glucose, blood pressure, and blood lipids.</p><p>The company plans to initiate a Phase 3 trial in China in due course.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>United Laboratories Reports Positive China Phase 2 Results for Obesity Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnited Laboratories Reports Positive China Phase 2 Results for Obesity Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-25 09:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ULIHF\">United Laboratories</a> International (HKG:3933) said its Phase 2 clinical trial of UBT251 Injection, a Class 1 innovative drug developed by its wholly owned unit, has been completed in Chinese patients with overweight and obesity, according to a Tuesday Hong Kong bourse filing.</p><p>Shares of the company gained over 3% in Wednesday morning trade.</p><p>The randomized, double-blind, placebo-controlled study enrolled 205 patients with obesity or overweight accompanied by at least one weight-related comorbidity.</p><p>Participants received weekly subcutaneous injections of UBT251 at 2 mg, 4 mg, or 6 mg, or placebo, over 24 weeks.</p><p>At week 24, the maximum mean reduction in body weight reached 19.7% or 17.5 kg in the UBT251 groups, compared with 2% or 1.6 kg in the placebo group.</p><p>The company said all dose groups demonstrated significant improvements in secondary endpoints, including waist circumference, blood glucose, blood pressure, and blood lipids.</p><p>The company plans to initiate a Phase 3 trial in China in due course.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03933","symbol_name":"联邦制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2614347778","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614347778","pubTimestamp":1771984131,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"United Laboratories International (HKG:3933) said its Phase 2 clinical trial of UBT251 Injection, a Class 1 innovative drug developed by its wholly owned unit, has been completed in Chinese patients w","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03933":"联邦制药","BK1191":"制药","UBCP":"联合合众银行","BK4211":"区域性银行"},"translate_title":"联邦制药报告肥胖药物中国2期结果积极","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UBCP":1.5,"03933":1},"content_text":"United Laboratories International (HKG:3933) said its Phase 2 clinical trial of UBT251 Injection, a Class 1 innovative drug developed by its wholly owned unit, has been completed in Chinese patients with overweight and obesity, according to a Tuesday Hong Kong bourse filing.Shares of the company gained over 3% in Wednesday morning trade.The randomized, double-blind, placebo-controlled study enrolled 205 patients with obesity or overweight accompanied by at least one weight-related comorbidity.Participants received weekly subcutaneous injections of UBT251 at 2 mg, 4 mg, or 6 mg, or placebo, over 24 weeks.At week 24, the maximum mean reduction in body weight reached 19.7% or 17.5 kg in the UBT251 groups, compared with 2% or 1.6 kg in the placebo group.The company said all dose groups demonstrated significant improvements in secondary endpoints, including waist circumference, blood glucose, blood pressure, and blood lipids.The company plans to initiate a Phase 3 trial in China in due course.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614347778","isCrawlerRequest":true}